The ROE as of September 2024 (TTM) for Halozyme Therapeutics, Inc. (HALO) is 168.60%

According to Halozyme Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 168.60%. This represents a change of 220.91% compared to the average of 52.54% of the last 4 quarters.

Halozyme Therapeutics, Inc. (HALO) Historical ROE (quarterly & annually)

How has HALO ROE performed in the past?

The mean historical ROE of Halozyme Therapeutics, Inc. over the last ten years is 74.11%. The current 168.60% ROE has changed 127.51% with respect to the historical average. Over the past ten years (40 quarters), HALO's ROE was at its highest in in the September 2016 quarter at 241.38%. The ROE was at its lowest in in the June 2016 quarter at -270.92%.

Halozyme Therapeutics, Inc. (HALO) ROE by Quarter and Year

Discovering the peaks and valleys of Halozyme Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Halozyme Therapeutics, Inc. (HALO) Average ROE

How has HALO ROE performed in the past?

The current ROE of Halozyme Therapeutics, Inc. (HALO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Halozyme Therapeutics, Inc. (HALO) ROE vs. Peers

How is HALO’s ROE compared to its peers?

Halozyme Therapeutics, Inc.’s ROE is greater than Agios Pharmaceuticals, Inc. (-47.05%), less than Insmed Incorporated (306.59%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Ultragenyx Pharmaceutical Inc. (-266.02%), less than BioMarin Pharmaceutical Inc. (5.08%), greater than Seagen Inc. (-28.06%), less than Alnylam Pharmaceuticals, Inc. (47.92%), less than Exelixis, Inc. (15.80%), greater than Alector, Inc. (-102.63%), greater than Legend Biotech Corporation (-23.20%), less than Ascendis Pharma A/S (251.76%), less than Cytokinetics, Incorporated (196.01%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Blueprint Medicines Corporation (-85.25%), greater than BeiGene, Ltd. (-14.93%), less than Inhibrx, Inc. (1.62%), less than Protagonist Therapeutics, Inc. (85.47%), greater than DICE Therapeutics, Inc. (-102.37%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Viridian Therapeutics, Inc. (-49.65%),

Build a custom stock screener for Halozyme Therapeutics, Inc. (HALO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Halozyme Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Halozyme Therapeutics, Inc. (HALO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Halozyme Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.